Business
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
- Companies will partner to develop novel antibody-drug conjugates using NBE’s unique ADC platform - - Agreement encompasses an exclusive option on multiple
About this update from Exelixis, Inc.
[{"type":"text","content":"\n- Companies will partner to develop novel antibody-drug conjugates using NBE’s unique ADC platform -\n\n\n- Agreement encompasses an exclusive option on multiple targets over a two-year term, with potential to extend time and scope of the collaboration -\n\n\n- Deal is the fourth biologics-focused agreement for Exelixis since 2018 -\n\n ALAMEDA, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--\nExelixis, Inc. (Nasdaq: EXEL) and NBE-Therapeutics today announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific conjugation and novel payloads. The agreement comes as Exelixis continues to build out its pipeline behind CABOMETYX® (cabozantinib), its flagship product that is now a global oncology franchise.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005562/en/\n\nUnder the terms of the agreement, Exelixis will make an upfront payment of $25 million to NBE in exchange for an exclusive option to nominate a defined number of target programs on NBE’s ADC platform over a two-year period. Together, the companies will seek to advance multiple ADCs into preclinical development with Exelixis contributing research and development support. For each individual target program, prior to filing an Investigational New Drug application, Exelixis will be able to exercise its option to an exclusive worldwide license, and afterwards continue clinical development and commercialization activities for that target program. Upon exercise of any option, NBE will be eligible for development and commercialization milestones, as well as royalties on net sales of any potential products resulting from that target program.\n\n\n“Exelixis is pursuing both internal drug discovery and external business development approaches to build a pipeline with the potential to make a difference for patients with cancer,” said Peter Lamb, Ph.D., Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis. “NBE-Therapeutics’ ADC technologies for conjugation and its novel anthracycline-based payload platform make it a strong partner for Exelixis as we seek to improve on conventional antibody-drug conjugate approaches. We’re loo...